<DOC>
	<DOCNO>NCT01932762</DOCNO>
	<brief_summary>This multi-site , open-label trial evaluate safety efficacy 100 mg grazoprevir ( MK-5172 ) use combination without 50 mg elbasvir ( MK-8742 ) and/or ribavirin ( RBV ) treat non-cirrhotic treatment-naïve participant chronic genotype ( GT ) 2 , 4 , 5 , 6 hepatitis C infection . In Part A randomization stratification ; GT2 participant assign arm A1 . In Part B , GT2 participant assign Arm B1 participant GT4 , GT5 GT6 randomize 1:1 ratio either Arm 3 Arm 4 stratification genotype .</brief_summary>
	<brief_title>Efficacy Safety Combination Grazoprevir ( MK-5172 ) + Elbasvir ( MK-8742 ) + Ribavirin ( RBV ) Genotype 2 Hepatitis C Infection ( MK-5172-047 )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>Parts A B : Body weight ≥50 kg ( 111 lb ) ≤ 125 kg ( 275 lb ) Has absence cirrhosis Agrees use two acceptable method birth control least 2 week prior Day 1 continue least 6 month last dose study drug , longer dictate local regulation ( female participant childbearing potential male participant female sexual partner childbearing potential ) . Part A : Has chronic HCV GT2 infection Part B : Has chronic HCV GT2 , GT4 , GT5 , GT6 infection Parts A B : Is treatment naïve ( participant previous treatment interferon , RBV , approve experimental direct act antiviral ( ) , investigational therapy HCV ) Is determine coinfected hepatitis B virus ( HBsAg positive ) HIV Has evidence , evaluation , hepatocellular carcinoma ( HCC ) Has clinical diagnosis substance abuse include follow specify drug within specify timeframes : Alcohol , intravenous drug , inhalational , psychotropics , narcotic , cocaine use , prescription overthecounter drug ( within 1 year screen visit ) , receive opiate agonist substitution therapy ( within 1 year screen visit ) , excessive historic marijuana use Has evidence active suspected malignancy , history malignancy , within last 5 year Female participant pregnant , lactating , expect conceive donate egg , childbearing potential unwilling commit two method birth control throughout treatment completion treatment , male participant planning impregnate provide sperm donation female sexual partner childbearing potential unwilling commit use two method birth control throughout treatment completion treatment Has evidence history chronic hepatitis cause HCV , include limited nonalcoholic steatohepatitis ( NASH ) , druginduced hepatitis , autoimmune hepatitis . Has uncontrolled diabetes ( document HbA1c &gt; 8.5 % ) Part A : Has non GT2 HCV infection Part B : Has HCV infection genotype GT2 , GT4 , GT5 GT6</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>